AJOYA Trademark

Trademark Overview


On Monday, December 14, 2015, a trademark application was filed for AJOYA with the United States Patent and Trademark Office. The USPTO has given the AJOYA trademark a serial number of 86848704. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 4, 2019. This trademark is owned by Warner Chilcott Company, LLC. The AJOYA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
ajoya

General Information


Serial Number86848704
Word MarkAJOYA
Filing DateMonday, December 14, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 4, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 31, 2016

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 18, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameALLERGAN PHARMACEUTICALS INTERNATIONAL L
Party Type21 - New Owner After Publication
Legal Entity Type77 - NOT AVAILABLE
AddressCOOLOCK, DUBLIN 17
IE

Party NameWarner Chilcott Company, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressFajardo 00738
PR

Party NameWarner Chilcott Company, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressFajardo 00738
PR

Trademark Events


Event DateEvent Description
Wednesday, February 19, 2020ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, March 4, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 4, 2019ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 18, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 16, 2018EXTENSION 4 GRANTED
Monday, July 16, 2018EXTENSION 4 FILED
Monday, July 16, 2018TEAS EXTENSION RECEIVED
Tuesday, December 12, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 8, 2017EXTENSION 3 GRANTED
Friday, December 8, 2017EXTENSION 3 FILED
Friday, December 8, 2017TEAS EXTENSION RECEIVED
Wednesday, June 28, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 27, 2017EXTENSION 2 GRANTED
Tuesday, June 13, 2017EXTENSION 2 FILED
Saturday, June 24, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 21, 2017AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, June 13, 2017TEAS EXTENSION RECEIVED
Tuesday, January 31, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 5, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 3, 2017EXTENSION 1 GRANTED
Tuesday, January 3, 2017EXTENSION 1 FILED
Tuesday, January 3, 2017TEAS EXTENSION RECEIVED
Tuesday, July 26, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 31, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 31, 2016PUBLISHED FOR OPPOSITION
Wednesday, May 11, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 28, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, April 21, 2016ASSIGNED TO LIE
Friday, April 8, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 5, 2016EXAMINER'S AMENDMENT ENTERED
Tuesday, April 5, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, April 5, 2016EXAMINERS AMENDMENT E-MAILED
Tuesday, April 5, 2016EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 30, 2016ASSIGNED TO EXAMINER
Friday, December 18, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, December 17, 2015NEW APPLICATION ENTERED IN TRAM